Neuropeptide Y

Neuropeptide Y (NPY)

Evidence & Status

  • Preliminary / Experimental
  • Preliminary

At a Glance

One of the most abundant neuropeptides in the brain, regulating appetite, stress resilience, anxiety, sleep, and cardiovascular tone. Strong preclinical evidence base; limited human data. Research interest highest in PTSD, stress resilience, and anxiety modulation.

Plain English

Neuropeptide Y is one of the most abundant signalling molecules in the brain and nervous system. It plays a central role in appetite — when NPY is released in the hypothalamus, it strongly stimulates hunger, and this is thought to be part of how the body defends against weight loss during dieting. It also appears to be deeply involved in how the brain responds to stress. Research in military special operations personnel found that soldiers with higher NPY responses to extreme stress performed better psychologically, and studies in people with post-traumatic stress disorder found that NPY levels in the brain were lower than in people without PTSD, suggesting that NPY may play a protective role in stress resilience. In the nervous system more broadly, NPY is studied for its potential calming effects on anxiety circuits, its role in promoting sleep, and its possible neuroprotective properties. Most of what we know comes from animal studies — human trials with exogenous NPY have been small. A practical challenge for research is that NPY breaks down very quickly in the body, and the fact that it stimulates appetite complicates dosing in contexts where that effect is unwanted.

Overview

An endogenous 36-amino acid neuropeptide first characterized by Tatemoto et al. in 1982, belonging to the pancreatic polypeptide family alongside PYY (peptide YY) and pancreatic polypeptide. NPY is one of the most abundant neuropeptides in the central nervous system and is expressed throughout the brain, peripheral nervous system, and immune cells. Acts through Y1, Y2, Y4, Y5, and Y6 receptor subtypes with distinct pharmacological profiles across receptor subtypes. Primary CNS roles include: potent appetite stimulation (orexigenic) from the arcuate nucleus, anxiolytic and stress-resilience effects via Y1 and Y2 receptors, regulation of circadian rhythms and sleep, modulation of memory consolidation, and neuroprotection. Peripherally, NPY is a major sympathetic neurotransmitter co-released with norepinephrine, contributing to vasoconstriction, cardiac regulation, and immune modulation. Research interest is highest in stress resilience, anxiety, PTSD, appetite regulation, and neuroprotection.

Research Summary

NPY has one of the largest preclinical evidence bases of any neuropeptide, with published animal studies spanning appetite, anxiety, stress, sleep, and neuroprotection, though human translational research remains limited. The most clinically developed research area is stress resilience and PTSD: human studies have found lower cerebrospinal fluid NPY levels in individuals with PTSD compared to trauma-exposed controls, and in special operations forces, higher NPY response to training stress correlated with better psychological performance under simulated captivity. Intranasal NPY administration studies in humans have explored acute anxiolytic effects, though sample sizes are small and dose optimization is ongoing. A key pharmacological challenge is the extremely short half-life (enzymatic inactivation by DPP-IV and NEP within minutes IV), the orexigenic CNS effects that limit appetite-related tolerability, and the lack of receptor-subtype selectivity of the endogenous peptide — which activates five Y receptor subtypes with distinct and sometimes opposing functional profiles. Selective Y2 agonists (which suppress feeding rather than stimulate it) and DPP-IV-resistant analogues represent the primary directions for therapeutic development.

Research Areas

  • Stress resilience & PTSD
  • Anxiety & anxiolysis
  • Appetite regulation (orexigenic)
  • Neuroprotection
  • Sleep & circadian modulation
  • Memory & learning
  • Cardiovascular regulation

Safety & Risks

Serious Risks

  • No established human safety profile for exogenous NPY administration; all available human pharmacology data comes from small controlled research studies
  • Cardiovascular effects — peripheral NPY acts as a vasoconstrictor at Y1 receptors and co-transmitter with norepinephrine; potential hemodynamic effects require careful monitoring
  • Metabolic effects — potent orexigenic signalling from hypothalamic NPY neurons; prolonged receptor activation could affect food intake regulation
  • Lack of receptor subtype selectivity with exogenous full-length NPY complicates safety prediction across CNS and peripheral compartments

Reported Side Effects

  • Appetite stimulation (orexigenic effect — may be undesirable outside controlled research contexts)
  • Transient vasodilation or vasoconstriction depending on route and dose
  • Blood pressure changes (sympathomimetic at peripheral Y1 receptors)
  • Sedation at higher doses (research context)
United States
Research only; no approved pharmaceutical indication
United Kingdom
Research only
Australia
Research only
Canada
Research only

Citations & Sources